Mesenchymal stem cells (MSCs) not only can be differentiated into different cell types but also have tropism towards injured or inflamed tissues serving as repair cells.
In this study we investigated the ability of PEG functionalized gold nanoparticles as non-viral vectors in the transfection of different cell lines, comparing them with commercial lipoplexes. Positively charged gold nanoparticles were synthesized using PEI as reducing and stabilizer agent and its cytotoxicity reduced by its functionalization with PEG. We bound the nanoparticles to three plasmids with different sizes (4-40 kpb). The vector internalization was evaluated by confocal and electronic microscopy. Its transfection efficacy was studied by fluorescence microscopy and flow cytometry. The application of the resulting vector in gene therapy was indirectly evaluated using ganciclovir in HeLa cells transfected to express the herpes virus thymidine kinase. An appropriate ratio between the nitrogen from the PEI and the phosphorous from the phosphate groups of the DNA together with a reduced size and an elevated electrokinetic potential are responsible for an increased nanoparticle internalization and enhanced protein expression when carrying plasmids of up to 40kbp (plasmid size close to the limit of the DNA-carrying capacity of viral vectors). Compared to a commercial transfection reagent, an equal or even higher expression of reporter genes (on HeLa and HEK 293T) and suicide effect on HeLa cells transfected with the herpes virus thymidine kinase gene were observed when using this novel nanoparticulated vector. Non-viral vectors based on gold nanoparticles covalently coupled with polyethylene glycol (PEG) and Polyethylenimine (PEI) can be used as efficient transfection reagents showing expression levels same or greater than the ones obtained with commercially available lipoplexes.
The main challenge of cancer treatment is to avoid or minimize systemic side effects in off-target tissues. Mesenchymal stem cells (MSCs) can be used as therapeutical carriers because of their ability to migrate and incorporate into inflammation areas including tumors. Here, this homing ability is exploited by carrying therapeutic nanoparticles (Hollow Gold Nanoparticles (HGNs)) following a “Trojan-horse” strategy. Amongst the different nanoparticles to be employed, HGNs have the capacity to resonate in the near infrared region when irradiated by an appropriated laser (808 nm). By transforming this absorbed energy into heat, they are capable to produce locally induced hyperthermia. At this wavelength healthy tissues have a minimal light absorption being the effect restricted to the tissues containing HGNs. By placing HGNs inside MSCs, the recognition, excretion and immune response are minimized. We demonstrate that MSCs internalize HGNs and reach the tumors still containing HGNs. After laser treatment this loaded cells are able to eradicate tumoral cells in vitro and in vivo without significant toxicity. Also Ki67 expression, which is usually correlated with proliferation, is reduced after treatment. This approach enhances the effectiveness of the treatment when compared to just the enhanced permeation and retention effect (EPR) of the HGNs by themselves.
11 February 2019 in Chemistry – A European Journal
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.